27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The machine learning model developed in this study demonstrated strong classification performance in detecting and differentiating depression, anxiety, and apathy. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There were 16,708 eligible encounters during the 12-month study period (June 2022-May 2023). 5 key findings →
Participants: 236 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We will assess the utility of auditory perceptual tests, both alone and combined with blood-based biomarkers (pTau217 and NfL), for diagnosis and prognosis in individuals with cognitive symptoms. 3 key findings →
Design: cohort study Participants: 600 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 6378 papers published between 2014 and 2023 were analyzed. 5 key findings →
Participants: 6,378 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Random forest classifier and feature selection procedures were used to select digital biomarkers. 1 key finding →
Participants: 1,324 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
11 variables were critical in the training phase, including educational level, depression, insomnia, age, Body Mass Index (BMI), medication count, gender, stenting, systolic blood pressure (sbp), neurosis and rapid eye movement. 4 key findings →
Design: cross-sectional Participants: 2,379 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
=0.03), indicating improved executive function. 5 key findings →
Design: randomized controlled trial Participants: 33 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study evaluates the efficacy, safety, and economics of galantamine in the treatment of Alzheimer disease (AD) patients, and to provide evidence-based reference for optimizing drug selection, dosing strategies, and reimbursement policies in clinical practice. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our study is well placed to evaluate the clinical utility of RMT assessments. 3 key findings →
Participants: 220 Evidence: low
Full summary, score breakdown and related studies → Original source
The ICA demonstrated convergent validity with MoCA (Pearson r=0.58, p<0.0001) and ACE (r=0.62, p<0.0001). 5 key findings →
Participants: 230 Evidence: low
Full summary, score breakdown and related studies → Original source
Previous studies have shown that the diagnostic performance of digital cognitive tests is comparable with that of conventional paper-and-pencil tests. 3 key findings →
Participants: 54 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These preliminary findings suggest that derived digital biomarkers may identify cognitive impairment in preclinical and prodromal AD, and may predict disease progression. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Analysis showed strong correlation between (1) XpressO memory tasks scores and the MoCA Memory Index Score (p-values < 0.001), and between (2) XpressO sub-test scores and MoCA total score (p-values < 0.005). 5 key findings →
Participants: 118 Evidence: low
Full summary, score breakdown and related studies → Original source
A total of 406 FHS (Framingham Heart Study) and 59 BHS (Bogalusa Heart Study) participants with traditional neuropsychological tests and digital assessments using the Defense Automated Neurocognitive Assessment (DANA) smartphone protocol were included. 5 key findings →
Participants: 406 Evidence: low
Full summary, score breakdown and related studies → Original source
Pupillometry is a measurement of pupil dilation commonly performed as part of neurological assessments. 1 key finding →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
Of 101 participants, 85 older adults without dementia (84.1%) who completed the study protocol were included in the statistical analysis. 5 key findings →
Participants: 51 Evidence: low
Full summary, score breakdown and related studies → Original source
Hypertension is associated with impaired cognition, and when combined with MCI, it may lead to a poor prognosis. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Of the respondents, 60/93 (65%) were women. 5 key findings →
Participants: 93 Evidence: low
Full summary, score breakdown and related studies → Original source
We established AD diagnostic models using plasma biomarkers for Chinese participants. 2 key findings →
Participants: 159 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In the amyloidogenic pathway associated with Alzheimer disease (AD), the amyloid precursor protein (APP) is cleaved by β-secretase to generate a 99-aa C-terminal fragment (C99) that is then cleaved by γ-secretase to generate the β-amyloid (Aβ) found in senile plaques. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The role of NPT has been largely explored in AD and dementia. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Machine learning does not differentiate clinically relevant disease categories yet. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Digital technology is transforming the development of drugs for Alzheimer's disease and was the topic of the Alzheimer's Association's Research Roundtable on its May 23-24, 2017 meeting. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Most inpatient users of VR described the experience as pleasant and capable of reducing pain and anxiety. 4 key findings →
Participants: 510 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a major neurodegenerative disease and the most common cause of dementia. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,109 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →